Mayne just what the medicine market needs

Mayne's new drug is well received by the market but is not a significant but is not a major earnings driver for the medium term.

News that Mayne Pharma Group (MYX) will start selling an authorised generic drug in the US has sent the stock surging to a more than two-year high this morning.

The drug supplier is now able to tap into a market worth around $US24 million a year with its authorised generic doxycycline hyclate tablet, which is used to treat certain types of bacterial infections.

{{content.question}}

{{ twilioFailed ? 'SMS Code Failed to Send…' : 'SMS Code Sent…' }}

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

We cannot send you a code via SMS to {{user.DayPhone}}

If you didn't receive SMS code please

SMS code cannot be sent due to: {{ twilioStatus }}

Please select one of the options below:

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device


Verify your mobile number to unlock a FREE trial

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa
Mastercard

The email address you entered is registered with InvestSMART.

Please login or select "Don't know password"

Please untick this box when using a public or shared device


Register as a new member

(using a different email)

Related Articles